Ixazomib 2.3 mg, 3 mg, 4 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 2.3 mg, 3 mg, 4 mg

Reference Brands: Ninlaro® (EU & US)

Category: Oncology Cancer Care

Ixazomib hard capsules 2.3 mg, 3 mg and 4 mg, an oral proteasome inhibitor used with lenalidomide and dexamethasone in multiple myeloma. For oncology pharmacies, importers and distributors.

Product Description:

Ixazomib was the first oral proteasome inhibitor. The capsule contains ixazomib citrate, which converts to ixazomib in the body and reversibly blocks the 20S proteasome. Myeloma cells make large amounts of protein and rely on the proteasome to clear it, so blocking it kills them. It comes as hard capsules of 4 mg, 3 mg and 2.3 mg. The 4 mg capsule is the starting dose; the lower strengths allow dose reductions and dosing in renal or hepatic impairment.

Ixazomib is used with lenalidomide and dexamethasone for adults with multiple myeloma who have had at least one prior therapy. The capsule is taken once weekly on days 1, 8 and 15 of a 28-day cycle, at least one hour before or two hours after food, swallowed whole and never opened or crushed. Platelet counts are monitored, as thrombocytopenia is common. Diarrhoea, constipation, peripheral neuropathy, rash and oedema need review. Strong CYP3A inducers such as rifampicin should be avoided.

Sourcing notes. Moisture protection matters: capsules stay in their original blister until the dose is taken, at room temperature. A pack usually holds the three capsules of one cycle, so order by packs per strength. Registration needs a CTD dossier, and patent and data protection should be checked in each market before generic supply. Ask for a CoA per batch, a site GMP certificate and a CoPP from the exporting authority. Ixazomib is a prescription-only anticancer medicine, and damaged capsules are handled with cytotoxic precautions. State strengths, packs, minimum shelf life and destination.